Dr. Choueiri on Next Steps for Pembrolizumab in RCC

In Partnership With:

Toni Choueiri, MD, discusses the next steps for the evaluation of pembrolizumab in the phase 3 KEYNOTE-564 trial (NCT03142334) in renal cell carcinoma.

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, discusses the next steps for the evaluation of pembrolizumab (Keytruda) in the phase 3 KEYNOTE-564 trial (NCT03142334) in renal cell carcinoma (RCC).

KEYNOTE-564 evaluated the efficacy and safety of single-agent pembrolizumab vs placebo in patients with RCC following nephrectomy. Updated disease-free survival (DFS) data from 30 months of follow-up were shared at the 2022 ASCO Genitourinary Cancer Symposium.

As follow-up and evaluation continue, investigators will accumulate data from more events to better determine any benefit in overall survival, Choueiri says. Additional end points such as second progression-free survival will also be examined, Choueiri concludes.

Related Videos
Brian A. Van Tine, MD, PhD
Jason Luke, MD, FACP
Katherine B. Peters, MD, PhD
Yasushi Goto, MD
Prithviraj Bose, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Jun Ma, MD
Hussein A. Tawbi, MD, PhD
Katsumori Asai, MD, PhD
Related Content